Prev Arrow Stocks

Johnson & Johnson ($JNJ) Stock Forecast: Up 4.1% Today

Morpher AI identified a bullish signal. The stock price may continue to rise based on the momentum of the good news.

What is Johnson & Johnson?

Johnson & Johnson (JNJ) is a diversified healthcare company and a leader in pharmaceuticals and medical devices. With a history dating back to 1886, the company has a global presence and a workforce of over 150,000 employees.

Why is Johnson & Johnson going up?

JNJ stock is up 4.1% on Jul 17, 2024 14:28

  • JNJ stock showed strong bullish momentum even as the company adjusted its guidance downwards.
  • The positive market response could be linked to Johnson & Johnson surpassing earnings expectations, although the stock price dropped due to revised guidance.
  • Investor attention may be directed towards JNJ's consistent growth and diverse business model, factors that have historically contributed to the company's ability to navigate different market environments successfully.
  • Despite concerns about the revised guidance, JNJ's history of steady earnings growth and sustainable dividend yield may be providing reassurance to investors and fueling the upward trend in the stock.

JNJ Price Chart

JNJ News

S&P 500, Nasdaq futures fall as tech shares shaken by China risk curbs

U.S. stocks were on track to pull back sharply from record highs on Wednesday, with technology stocks under double pressure from concerns about U.S. export restrictions on China and Donald Trump’s stance on Taiwan. Futures on the tech-heavy Nasdaq 100 Index (NQ=F) led the declines, falling 1.4%, while futures on the S&P 500 Index (ES=F) fell 1%. Dow Jones Industrial Average (YM=F) futures fell 0.3% after the index jumped 700 points on Tuesday to close at an all-time high. Stocks fell as concerns about the risks to technology companies grew, overshadowing the high hopes for interest rate cuts that have fueled the rally in recent days. Those concerns weighed on the big companies whose artificial intelligence-powered gains have helped push the S&P 500 to fresh records this year, with chipmaker Nvidia (NVDA) falling more than 4% in premarket trading. The Biden administration has told allies it is considering tougher restrictions on companies that continue to make advanced chip technology available to China despite existing export restrictions, Bloomberg News Agency reported Shares of ASML (ASML, ASML.AS), which has been mentioned as a potential target, fell more than 8% after the Dutch chip equipment maker reported strong quarterly earnings.

https://www.lankatimes.com/sp-500-nasdaq-futures-fall-as-tech-shares-shaken-by-china-risk-curbs/

News Article Image S&P 500, Nasdaq futures fall as tech shares shaken by China risk curbs

3 Dividend Stocks With 3%+ Yields to Upgrade Your Annual Income

If you are a passive income investor like me, you will always be on the lookout for high-yield dividend stocks. However, not all stocks are made equal. Some companies might pay dividends but the payment may not be sustainable and this can put your regular income at risk. On the other hand, some companies might pay a very high dividend when they make strong profits and cut down the dividend payout when the profit drops. As a smart investor, it is essential to look for companies that pay steady dividends and have the free cash flow to be able to sustain the same. A dividend yield shows the percentage of the company’s share price paid in the form of a dividend. When picking high-yield dividend stocks, it is important to watch out for the dividend yield and the payout ratio.   While a high-dividend yield is attractive, a number over 5% can be risky. It is best to look for a dividend yield in the range of 2% to 4%. I’ve picked out three dividend stocks with a 3%+ yield that will upgrade your annual income. Let’s take a look at them.

https://investorplace.com/2024/07/3-dividend-stocks-with-3-yields-to-upgrade-your-annual-income/

News Article Image 3 Dividend Stocks With 3%+ Yields to Upgrade Your Annual Income

Johnson & Johnson Beats, But Falls On Lowered Guidance

Johnson & Johnson Earnings Top, But Dow Stock Falls On Lowered Guidance Investor's Business Daily ...

https://www.investors.com/news/technology/johnson-johnson-stock-johnson-johnson-earnings-q2-2024/

News Article Image Johnson & Johnson Beats, But Falls On Lowered Guidance

ASML, United Airlines And 3 Other Stocks To Watch Heading Into Wednesday

With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Johnson & Johnson (NYSE: JNJ ) to report quarterly earnings at $2.70 per share on revenue of $22.31 billion before the opening bell, according to data from Benzinga Pro . Johnson & Johnson shares gained 0.5% to $151.80 in after-hours trading. Spirit Airlines Inc . (NYSE: SAVE ) issued soft second-quarter preliminary revenue estimates. The company estimated total … Full story available on Benzinga.com

https://www.benzinga.com/news/earnings/24/07/39809435/asml-united-airlines-and-3-other-stocks-to-watch-heading-into-wednesday

News Article Image ASML, United Airlines And 3 Other Stocks To Watch Heading Into Wednesday

3 Safe Dividend Kings to Recession-Proof Your Portfolio

Income investors should focus on stocks that pay solid yields, but also those that have sustainable payouts and strong business models. Dividend kings are an excellent place to look for stocks with sustainable dividends. These are companies that have raised their dividends each year for more than 50 consecutive years. The following three dividend kings have low dividend payout ratios and recession-proof business models, meaning their dividends are well-covered even when the economy is suffering. Walmart (WMT) Source: Alexanderstock23 / ShutterstockWalmart (NYSE:WMT) traces its roots back to 1945 when Sam Walton opened his first discount store. The company has since grown into the largest retailer in the world, serving more than 230 million customers each week. Revenue should be around $668 billion this year. This dividend king posted first quarter earnings in May, and results were better than expected on both the top and bottom lines — and by wide margins in both cases. Adjusted earnings-per-share came to 60 cents, which was eight cents ahead of expectations. Revenue was up 6% year-over-year to $161.5 billion. This was a staggering $3.36 billion better than estimates. Global ecommerce sales soared 21% higher year-on-year, which was led by store-fulfilled pickup and delivery, as well as good performances from the company’s marketplace. Global advertising revenue also rose 24%, including Walmart Connect in the US. Comparable sales in the US rose 3.8%, which was 40 basis points ahead of estimates. Transactions were up 3.8%, while the average ticket size was flat to a year ago. For Sam’s Club, ecommerce sales rose 21% and contributed 280 basis points to comparable sales. Walmart’s competitive advantage is in its enormous size, as it can buy and ship product at scale, which few retailers can compete with. This allows it to operate with low prices to consumers and — as more than half of its revenue comes from groceries — its recession performance is excellent. The company’s payout ratio is quite low at 34% expected for the full fiscal year, making for a conservative dividend policy. The dividend should be very safe, even in a recession. Walmart has increased its dividend for 51 years. Hormel Foods (HRL) Source: monticello / ShutterstockHormel Foods (NYSE:HRL) was founded in 1891 in Minnesota. Since that time, the company has grown into a $17 billion market capitalization juggernaut in the food products industry with over $12 billion in annual revenue. This dividend king has kept its core competency as a processor of meat products for well over a hundred years. But it’s also grown into other business lines through acquisitions. With products in 80 countries worldwide, Hormel’s portfolio of brands includes Skippy, SPAM, Justin’s and more than 30 others. Admittedly, the results of Hormel’s second quarter earnings were somewhat weak. Revenue was off 3% year-over-year to $2.89 billion and missed estimates by $80 million. Sales also fell in the retail and international segments. However, earnings-per-share were two cents ahead of estimates and gross margin was 17.5% of revenue — 100 basis points better than expected. Guidance for this year is for sales growth of 1% to 3%, with a slightly raised earnings estimate. Irrespective of those results, the company has a track record of consistent results from a steady stream of acquisitions and some organic growth. This has afforded Hormel the ability to consistently raise its dividend, securing its status as a safe dividend king. I’m forecasting forward earnings growth of 5% annually as Hormel could grow more slowly than it has in the past. (Sales growth is the primary driver of earnings-per-share expansion moving forward.) Hormel’s main competitive advantage is its ~40 products that are either #1 or #2 in their category. Hormel has brands that are proven, and that leadership position is difficult for competitors to supplant. In addition, the company has a global network of distributors that few food companies can rival. It’s also worth mentioning that Hormel’s earnings-per-share actually grew during the Great Recession while most of the world was in rather dire straits. That’s a testament to the company’s defensive nature. Hormel has increased its dividend for 58 consecutive years. Johnson & Johnson (JNJ) Source: Michael Vi / ShutterstockJohnson & Johnson (NYSE:JNJ) is a diversified health care company and a leader in the area of pharmaceuticals and medical devices. The company was founded in 1886 and employs more than 150,000 people around the world. According to first quarter earnings reports, revenue grew 2.3% to $21.4 billion, which was in-line with estimates. Adjusted earnings-per-share of $2.71 compared to $2.68 in the prior year and was $0.06 better than expected. Excluding Covid-19 vaccine sales, the company’s revenue total grew 7.7% in the first quarter. Revenue for Innovative Medicines improved 1.1% on a reported basis, but was higher by 8.3% when excluding currency translation. Infectious Disease fell more than 48%, mostly due to reduced Covid-19 vaccine revenue. Oncology continues to act well, with revenue up 17.1% due to continued strength in Darzalex, which treats multiple myeloma. Johnson & Johnson has grown earnings over the past 10 years at a rate of 6.3%. A diversified business model and stable growth have allowed the company to grow earnings before, during and after the last recession, showing that its products are in demand regardless of market conditions. We expect earnings-per-share to grow at a rate of 6% per year through 2029 due to gains in revenue and share repurchases. With a dividend that has increased for 62 consecutive years, Johnson & Johnson has a reasonably low payout ratio of approximately 46% for 2024. This gives the company ample room to raise its dividend, even in a prolonged recession. On the date of publication, Bob Ciura did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article. Bob Ciura has worked at Sure Dividend since 2016. He oversees all content for Sure Dividend and its partner sites. Prior to joining Sure Dividend, Bob was an independent equity analyst. His articles have been published on major financial websites such as The Motley Fool, Seeking Alpha, Business Insider and more. Bob received a bachelor’s degree in Finance from DePaul University and an MBA with a concentration in investments from the University of Notre Dame.

https://investorplace.com/2024/07/3-safe-dividend-kings-to-recession-proof-your-portfolio/

News Article Image 3 Safe Dividend Kings to Recession-Proof Your Portfolio

Johnson & Johnson Price History

26.05.2023 - JNJ Stock was down 1.2%

  • JMG Financial Group Ltd. reduced its position in JNJ by 4.2%, which could have contributed to the bearish movement.
  • Mayflower Financial Advisors LLC increased its stake in JNJ by 7.1%, which could have offset the bearish movement.
  • The news about BlackRock's control over companies, including JNJ, may have caused uncertainty and contributed to the bearish movement.
  • The article about the AI tool that beat out top Wall Street analysts may have also caused investors to question the value of traditional analysis methods and contributed to the bearish movement.

06.08.2023 - JNJ Stock was down 2.3%

  • The bearish movement of JNJ stock today can be attributed to the following factors:
  • 1. Market sentiment: The overall market sentiment might be bearish, leading to a decline in JNJ stock along with other stocks.
  • 2. Cidara Therapeutics announcement: The news about Cidara Therapeutics announcing Janssen's election to proceed under its license agreement relating to novel drug-Fc conjugates targeting influenza may have impacted JNJ stock negatively. This announcement could indicate potential competition in the influenza treatment market, affecting investor confidence in JNJ's pharmaceutical division.
  • 3. Idorsia deal with Janssen Biotech: The news of Idorsia reaching a deal with Janssen Biotech, affiliated with Johnson & Johnson, for the return of rights for Aprocitentan might have caused some uncertainty among investors. This deal could have implications for JNJ's future drug development pipeline and potentially affect its revenue prospects.
  • 4. Arm's IPO ambitions: The news of Arm halving its IPO ambitions to $4.87 billion, surpassing the listing of Johnson & Johnson consumer health spinoff Kenvue, could have indirectly impacted JNJ stock. This news might have shifted investor attention away from JNJ, leading to a decline in its stock price.
  • Overall, the bearish movement of JNJ stock today could be influenced by a combination of market sentiment, competition in the influenza treatment market, uncertainty surrounding future drug development, and the diversion of investor attention to other IPOs.

19.06.2023 - JNJ Stock was down 0.3%

  • JNJ stock experienced a strong bearish movement today.
  • The company was ordered to pay $18.8 million in a talc-related trial, adding to the ongoing litigation surrounding its baby powder.
  • JNJ joined other pharmaceutical companies in taking legal action against the U.S. government's drug pricing negotiation program, which could potentially impact the company's profits.
  • Despite the bearish movement, Wealth Enhancement Advisory Services LLC showed confidence in JNJ's growth potential by increasing its holdings in the company during the first quarter.
  • Overall, the negative legal developments and concerns over potential profit limitations due to the drug pricing negotiation program likely contributed to the bearish movement in JNJ stock today.

20.06.2023 - JNJ Stock was up 4.4%

  • The bullish movement in JNJ stock today can be attributed to the following factors:
  • 1. Strong Q2 Earnings: Johnson & Johnson reported better-than-expected Q2 earnings, with adjusted earnings per share of $2.80, beating the consensus of $2.62. Sales also increased by 6.3% to $25.5 billion, surpassing the consensus of $24.63 billion. This positive financial performance likely contributed to the bullish market movement.
  • 2. Positive Jobs Data: The Australian job market showed better-than-expected results, with an addition of 32.6K jobs, surpassing the expected 15.4K. This positive employment data may have had a spillover effect on JNJ stock, as it indicates a strong economy and potential increased demand for healthcare products.
  • 3. Overall Market Sentiment: The broader market sentiment, with the Dow industrial average rising for the 8th consecutive day and the S&P index and Dow industrial average having risen 7 of the last 8 trading days, may have also influenced the bullish movement in JNJ stock.
  • 4. DARZALEX Sales: Genmab reported strong worldwide net trade sales of DARZALEX, a product co-developed with Johnson & Johnson. This positive sales report may have indirectly impacted the market sentiment towards JNJ stock.
  • Overall, the combination of strong earnings, positive jobs data, favorable market sentiment, and positive sales reports contributed to the bullish movement in JNJ stock today.

17.06.2024 - JNJ Stock was up 4.1%

  • JNJ stock showed strong bullish momentum even as the company adjusted its guidance downwards.
  • The positive market response could be linked to Johnson & Johnson surpassing earnings expectations, although the stock price dropped due to revised guidance.
  • Investor attention may be directed towards JNJ's consistent growth and diverse business model, factors that have historically contributed to the company's ability to navigate different market environments successfully.
  • Despite concerns about the revised guidance, JNJ's history of steady earnings growth and sustainable dividend yield may be providing reassurance to investors and fueling the upward trend in the stock.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.